Regorafenib (BAY 73-4506), Inhibitor

Regorafenib (BAY 73-4506)

Cat. Num. AAA385671

• Purity: >98%
• Synonyms: Regorafenib (BAY 73-4506); inhibitor

• Purity/Purification: >98%
• Concentration: 0.1 mM: 20.71 mL (1 mg); 103.56 mL (5 mg); 207.13mL (10 mg); 0.5 mM: 4.14 mL (1 mg); 20.71 mL (5 mg); 41.43 mL (10 mg); 1 mM: 2.07 mL (1 mg); 10.36 mL (5 mg); 20.71 mL (10 mg); 5 mM: 0.41 mL (1 mg); 2.07 mL (5 mg); 4.14 mL (10 mg) (varies by lot)

• CAS Number: 755037-03-7
• Formula: C21H15ClF4N4O3
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
• In Vivo Solvent: 2% DMSO+30% peg 300+5% Tween 80+ddH2O
• Solubility (DMSO): 89 mg/mL (200.9 mM)
• Solubility (Ethanol): Insoluble
• Solubility (in vivo): 4 mg/mL
• Solubility (Water): Insoluble
• Availability: We cannot ship this item to Switzerland, Italy, Germany, France and Austria.
• Preparation and Storage: Store at -20 degree C for 6 months (Solution base)

Chemical Structure

Testing Data (TD)

(Targets)

Related Product Information for Regorafenib (BAY 73-4506), inhibitor

Regorafenib (BAY 73-4506) is a multikinase inhibitor with IC50 of 17, 40 and 69 nM c-KIT, VEGFR2, B-Raf. Regorafenib (BAY 73-4506) is an orally bioavailable multikinase inhibitor targeting both the tumor and its vasculature.

References

Takeshi Uenaka, .et al. In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson-s disease, Hum Mol Genet, 2018, Nov 15; 27(22): 3974-3985 PMID: 30137437
Yi Xu, .et al. Knockdown of delta-5-desaturase promotes the anti-cancer activity of dihomo-γ-linolenic acid and enhances the efficacy of chemotherapy in colon cancer cells expressing COX-2, Free Radic Biol Med, 2016, Jul; 96: 67-77 PMID: 27101738